touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy) to discuss the challenges that arise in treating patients with myasthenia gravis.
The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was presented at the 7th Congress of the European Academy of Neurology (EAN) – Virtual 2021.
- What are the challenges in the treatment of patients with myasthenia gravis? (0:19)
Disclosures: Renato Mantegazza has received funding for Travel or Meeting attendance from, Alexion, Argenx, Biomarin Novartis, Catalyst, Merck Serono, UCB, and for Advisory Board participation from Alexion, Argenx, UCB, Regeneron.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of the EAN Congress, Virtual 2021.
Share this Video
Related Videos In Rare Diseases
Lisa Sarfaty: Help support Rare Disease Day
Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February. These activities are aimed at raising awareness about rare diseases and the challenges faced by people living with these conditions. In this video, Lisa Sarfaty, NORD’s VP of Communication and Engagement, […]
Lisa Sarfaty: Exploring and addressing inequities in rare diseases
Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization for Rare Disorders) and explore ways in which they could be tackled. Questions Could you […]
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!